• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

关于新型药物 Lumateperone(ITI-007)在精神和神经障碍方面的证据。

Evidence on the New Drug Lumateperone (ITI-007) for Psychiatric and Neurological Disorders.

机构信息

Institute of Psychiatry and Psychology, Department of Geriatrics, Neuroscience and Orthopedics, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.

Department of Science, University of Rome "Roma Tre", Rome, Italy.

出版信息

CNS Neurol Disord Drug Targets. 2020;19(4):243-247. doi: 10.2174/1871527319666200601145653.

DOI:10.2174/1871527319666200601145653
PMID:32479249
Abstract

Lumateperone (ITI-007) is a tosylate salt with binding affinities to receptors implicated in the therapeutic actions of antipsychotic medications, including the serotonin 5HT2A receptors, dopamine D2 and D1 receptors and the serotonin transporter. It has a unique mechanism of action because it simultaneously modulates serotonin, dopamine, and glutamate neurotransmission, implicated in serious mental illness. It can be considered a multi-target-directed ligand and a multifunctional modulator of serotoninergic system with possible precognitive, antipsychotic, antidepressant and anxiolytic properties. Lumateperone has been investigated as a novel agent for the treatment of schizophrenia, but it represents a new potential option for other psychiatric and neurological diseases, such as behavioural symptoms of dementia or Alzheimer's disease, sleep disturbances, bipolar depression. Besides, it has demonstrated a favourable safety profile without significant extrapyramidal side effects, hyperprolactinemia or changes in cardiometabolic or endocrine factors versus placebo. Additional studies are warranted to confirm and examine the benefit of lumateperone and possible therapeutic targets. This paper is a comprehensive and thorough summary of the most important findings and potential future role of this particular compound in personalized treatments.

摘要

鲁马替培酮(ITI-007)是一种甲苯磺酸盐,与抗精神病药物治疗作用相关的受体具有亲和力,包括 5HT2A 受体、多巴胺 D2 和 D1 受体以及血清素转运体。它具有独特的作用机制,因为它同时调节血清素、多巴胺和谷氨酸神经递质,这与严重的精神疾病有关。它可以被认为是一种多靶点配体和血清素能系统的多功能调节剂,具有潜在的预知、抗精神病、抗抑郁和抗焦虑作用。鲁马替培酮已被研究作为一种新型治疗精神分裂症的药物,但它也可能是其他精神和神经疾病的新选择,如痴呆或阿尔茨海默病的行为症状、睡眠障碍、双相抑郁。此外,与安慰剂相比,它具有良好的安全性,没有明显的锥体外系副作用、高催乳素血症或心血管代谢或内分泌因素的变化。需要进一步的研究来证实和检查鲁马替培酮的益处和可能的治疗靶点。本文全面而深入地总结了这种特殊化合物在个体化治疗中的最重要发现和潜在的未来作用。

相似文献

1
Evidence on the New Drug Lumateperone (ITI-007) for Psychiatric and Neurological Disorders.关于新型药物 Lumateperone(ITI-007)在精神和神经障碍方面的证据。
CNS Neurol Disord Drug Targets. 2020;19(4):243-247. doi: 10.2174/1871527319666200601145653.
2
Lumateperone: a new treatment approach for neuropsychiatric disorders.鲁马西酮:一种治疗神经精神疾病的新方法。
Drugs Today (Barc). 2018 Dec;54(12):713-719. doi: 10.1358/dot.2018.54.12.2899443.
3
Dopamine D receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia.卢美哌隆(ITI-007)的多巴胺 D 受体占有率:精神分裂症患者的正电子发射断层扫描研究。
Neuropsychopharmacology. 2019 Feb;44(3):598-605. doi: 10.1038/s41386-018-0251-1. Epub 2018 Oct 26.
4
An evaluation of lumateperone tosylate for the treatment of schizophrenia.硫酸鲁拉西酮治疗精神分裂症的评价。
Expert Opin Pharmacother. 2020 Feb;21(2):139-145. doi: 10.1080/14656566.2019.1695778. Epub 2019 Nov 30.
5
Lumateperone: New Drug or Same Old Drug With a New Dress?鲁马替培隆:新药还是换汤不换药?
J Psychosoc Nurs Ment Health Serv. 2020 Jun 1;58(6):9-12. doi: 10.3928/02793695-20200513-01.
6
A review of the pharmacology and clinical profile of lumateperone for the treatment of schizophrenia.一项关于lumateperone 治疗精神分裂症的药理学和临床特征的综述。
Adv Pharmacol. 2021;90:253-276. doi: 10.1016/bs.apha.2020.09.001. Epub 2020 Sep 29.
7
Lumateperone: A Novel Antipsychotic for Schizophrenia.卢美哌隆:一种用于精神分裂症的新型抗精神病药。
Ann Pharmacother. 2021 Jan;55(1):98-104. doi: 10.1177/1060028020936597. Epub 2020 Jun 26.
8
Lumateperone: First Approval.卢马替喷:首次批准。
Drugs. 2020 Mar;80(4):417-423. doi: 10.1007/s40265-020-01271-6.
9
Design of novel dopamine D and serotonin 5-HT receptors dual antagonists toward schizophrenia: An integrated study with QSAR, molecular docking, virtual screening and molecular dynamics simulations.新型多巴胺 D 和血清素 5-HT 受体双重拮抗剂设计用于治疗精神分裂症:基于 QSAR、分子对接、虚拟筛选和分子动力学模拟的综合研究。
J Biomol Struct Dyn. 2020 Feb;38(3):860-885. doi: 10.1080/07391102.2019.1590244. Epub 2019 Mar 27.
10
Lumateperone for the Treatment of Schizophrenia.用于治疗精神分裂症的卢马替喷。
Psychopharmacol Bull. 2020 Sep 14;50(4):32-59.

引用本文的文献

1
Unlocking the potential of lumateperone and novel anti-psychotics for schizophrenia.释放鲁马西酮及新型抗精神病药物治疗精神分裂症的潜力。
Bioimpacts. 2024 Sep 9;15:30259. doi: 10.34172/bi.30259. eCollection 2025.
2
Exploring the Pharmacological and Clinical Features of Lumateperone: A Promising Novel Antipsychotic.探索鲁马哌酮的药理和临床特征:一种有前景的新型抗精神病药物。
Int J Mol Sci. 2024 Dec 11;25(24):13289. doi: 10.3390/ijms252413289.
3
Future Therapeutic Strategies for Alzheimer's Disease: Focus on Behavioral and Psychological Symptoms.
阿尔茨海默病的未来治疗策略:关注行为和心理症状。
Int J Mol Sci. 2024 Oct 22;25(21):11338. doi: 10.3390/ijms252111338.
4
The Novel Antipsychotic Lumateperone (Iti-007) in the Treatment of Schizophrenia: A Systematic Review.新型抗精神病药物鲁马哌酮(ITI-007)治疗精神分裂症的系统评价
Brain Sci. 2023 Nov 26;13(12):1641. doi: 10.3390/brainsci13121641.
5
Recent Advances in Psychopharmacology: From Bench to Bedside Novel Trends in Schizophrenia.精神药理学的最新进展:从实验室到临床 精神分裂症的新趋势
J Pers Med. 2023 Feb 25;13(3):411. doi: 10.3390/jpm13030411.
6
The role of lumateperone in the treatment of schizophrenia.鲁马哌酮在精神分裂症治疗中的作用。
Ther Adv Psychopharmacol. 2021 Jul 31;11:20451253211034019. doi: 10.1177/20451253211034019. eCollection 2021.